Daniel J. Renouf
Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Daniel J. Renouf

Vancouver, BC, CA 
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Vancouver, BC, CA 
OverviewLocationsClinical Research

Overview

Daniel Renouf practices in Vancouver, Canada. Mr. Renouf is rated as an Experienced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Male

Locations

Vancouver, BC, Canada
Other Locations
BC Cancer
Surrey, BC V3V1Z2, Canada
BC V5Z4E6, Canada
Victoria, BC, Canada
Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Biological, Procedure
Study Drugs: Pembrolizumab, Ziv-Aflibercept
Study Phase: Phase 1
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX
Enrollment Status: Terminated
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: SLC-0111, Gemcitabine
Study Phase: Phase 1/Phase 2
An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 04, 2022
Intervention Type: Drug
Study Drugs: mFolfirinox, Gemcitabine
Study Phase: Phase 3
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
Enrollment Status: Withdrawn
Publish Date: February 07, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)
A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction
A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction
Enrollment Status: Withdrawn
Publish Date: April 24, 2017
Intervention Type: Other, Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

158 Total Publications

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Renouf's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile